According to a genetic medicine publication released in June 2021, an extensive illness load is caused by a subclass of genetic disorders known as autosomal recessive (AR) diseases, which afflict 1.7–5 in 1000 newborns (compared to 1.4 in 1000 for autosomal dominant disorders). In other populations, AR illness’s prevalence may be far higher. More than 2000 genetic diseases with AR inheritance will be known by 2020.
Access Full Report @ https://www.databridgemarketresearch.com/es/reports/global-gene-therapy-market
Data Bridge Market Research analyses that the Gene Therapy Market is expected to grow at a CAGR of 18.3% from 2023 to 2030 and is expected to reach USD 28,167.69 million by 2030. The viral vector is projected to propel the market’s growth as they are widely used in gene therapy to diagnose genetic disorders in various regions, and more advanced technologies are available. Especially these viral vectors have a broad range of applications for research and clinical purposes, including adenovirus, retrovirus, lentivirus, adeno- associated virus, vaccinia virus, herpes simplex virus, and others.
Key Findings of the Study
Increasing Prevalence of Genetic Disorders
A sizable share of prenatal and neonatal mortality in several nations in the Region is caused by genetic and congenital diseases. Many multifactorial ailments are often caused by genetic factors as well. Gene alterations that are essentially present in every cell in the body cause many hereditary diseases. These illnesses thus frequently impact many bodily systems, and the majority cannot be treated.
Mutations, and exposure to chemicals and radiation, among other things, can all result in genetic disorders. Although some ailments have been treated with gene therapy, most treatment plans for genetic disorders do not change the underlying genetic abnormality. For this, the prevalence of genetic abnormalities is significantly rising across all age groups, and practically all geographic areas are expected to act as a driver for the growth of the global gene therapy market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research Institutes, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Rest of Middle East and Africa, Brazil, and Rest of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Kite Pharma (a subsidiary of Gilead Sciences, Inc.) (Switzerland), uniQure NV. (Netherlands), Oxford Biomedica (U.K.), Spark Therapeutics, Inc. (U.S), SIBONO (China), bluebird bio, Inc. (U.S), Shanghai Sunway Biotech Co., Ltd. (China), Biogen (U.S.), Dendreon Pharmaceuticals LLC. (U.S), Amgen Inc. (U.S.), AnGes, Inc. (Japan), Enzyvant Therapeutics GmbH (U.S.), AGC Biologics (U.S), Janssen Pharmaceuticals, Inc. (U.S), CHIESI Farmaceutici S.p.A. (Italy), Bristol-Myers Squibb Company (U.S), Mallinckrodt (Ireland), Orchard Therapeutics plc, (U.K.), and Ferring B.V. (Switzerland) among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The gene therapy market is segmented on the basis of vector type, method, application, and end user.
- On the basis of vector type, the global gene therapy market is segmented into viral vector and non- viral vector.
In 2022, the viral vector segment of product type segment is anticipated to dominate the gene therapy market.
In 2022, the viral vector segment of this market will dominate the gene therapy market due to the due to potent antibody response and for eliminating of pathogen infected cells. The viral vector segment is expected reach the highest CAGR of 19.1% in the forecast period of 2023-2030.
- On the basis of method, the global gene therapy market is segmented into ex vivo and in vivo. In 2023, the ex vivo segment is expected to dominate the global gene therapy market with 75.70% market share due to the advancements and innovation in the approaches of gene therapy.
- On the basis of application, the global gene therapy market is segmented into oncological disorders, cardiovascular diseases, infectious diseases, rare diseases, neurological disorders and other diseases. In 2023, the oncological disorders segment is expected to dominate the global gene therapy market with 46.05% market share due to rising prevalence of cancer and the early diagnosis of the diseases among the population.
- On the basis of end user, the global gene therapy market is segmented into cancer institutes, hospitals, research institutes and others. In 2023, the cancer institute’s segment is expected to dominate the global gene therapy market with 43.87% market share due to rising demand of personalized medicines or gene therapy for diagnosis of the diseases worldwide.
- On the basis of end user, the global gene therapy market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, academic institutes and others. The hospitals segment is expect staged to dominate the market with 46.53% market share due to the increasing adoption of advanced products as well as rising healthcare concern of the patient over the past few years.
Major Players
Data Bridge Market Research recognizes the following companies as the major gene therapy market players in gene therapy market are Novartis AG (Switzerland), Kite Pharma (a subsidiary of Gilead Sciences, Inc.) (Switzerland), uniQure NV. (Netherlands), Oxford Biomedica (U.K.), Spark Therapeutics, Inc. (U.S), SIBONO (China), bluebird bio, Inc. (U.S), Shanghai Sunway Biotech Co., Ltd. (China), Biogen (U.S), Dendreon Pharmaceuticals LLC. (U.S), Amgen Inc. (U.S), AnGes, Inc. (Japan), Enzyvant Therapeutics GmbH (U.S), AGC Biologics (U.S), Janssen Pharmaceuticals, Inc. (U.S), CHIESI Farmaceutici S.p.A. (Italy), Bristol-Myers Squibb Company (U.S), Mallinckrodt (Ireland), Orchard Therapeutics plc, (U.K.), and Ferring B.V. (Switzerland) among others.
Market Developments
- In February 2023, UniQure N.V. stated that the crucial HOPE-B clinical research, which examined the effectiveness, longevity, and safety of HEMGENIX®, had results published in the New England Journal of Medicine (NEJM) (Vol. 388 No. 8). (etranacogene dezaparvovec-drlb). UniQure oversaw the multi-year clinical development of HEMGENIX®, and after it obtained the global commercialization rights to the medication, CSL took over sponsorship of the clinical studies. The U.S. Food and Drug Administration (FDA) and the European Commission (EC) both gave their approval to HEMGENIX® in November 2022 and February 2023, respectively, for use in the European Union.
- In January 2023, Novartis AG Since its first release, we have worked to increase access to Zolgensma® (onasemnogene abeparvovec), working collaboratively with regional authorities and payers to develop creative access strategies that allow qualified individuals with spinal muscular atrophy (SMA) to obtain the gene therapy. Together with these ground-breaking access strategies, we also introduced the first global Managed Access Program (gMAP) for a single gene treatment in early 2020. Along with our earlier US controlled access programme, we were able to give our gene therapy free of charge to approximately 300 children in 36 other countries through that initiative, which was accessible in those where Zolgensma had not yet gotten approval or where there was no access road.
- In December 2022 Kite Pharma, Inc., and Daiichi Sankyo Co., Ltd. announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma. Only patients who have not previously had a transfusion of CAR T cells directed against the CD19 antigen should be treated with Yescarta.
- In September 2022, Oxford Biomedica announced that has signed a new Licence and Supply Agreement ("LSA") with an unnamed US-based late-stage cell and gene therapy startup. The LSA establishes a five-year clinical supply agreement and offers the new partner a non-exclusive licence to use Oxford Biomedica's LentiVector® platform for its principal development, a cell-based treatment that targets a rare indication.
- In September 2022, AnGes, Inc. hereby announces that it has decided to discontinue the development of an HGF gene therapy product it has been working on for the additional indication of chronic arterial occlusivedisease with rest pain in Japan.
- In June 2022, Biogen announced that the efficacy of SPINRAZA in enhancing the quality of life for people with spinal muscular atrophy (SMA), it also released new research supporting the continued development of an exploratory higher dose of SPINRAZA. These findings will be discussed at the June 9–11, 2021, virtual Cure SMA Research & Clinical Care Conference.
- In March 2022, Bristol Myers Squibb Company and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022.This acquisition has helped the company to increase the global presence in the market.
Regional Analysis
Geographically, the countries covered in the advanced wound care market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey and the rest of Europe as a part of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines and the rest of Asia-Pacific as a part of Asia Pacific, South Africa and rest of Middle East and Africa as a part of Middle East and Africa, Brazil and rest of South America as a part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in gene therapy market during the forecast period 2023 - 2030
In 2022, North America dominated the gene therapy market owing to the higher level of investments by U.S. manufacturers and increasing prevalence of oncological diseases and chronic disorders such as cancer diagnostics in U.S. North America will continue to dominate the gene therapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and launch of new gene therapy products in this region. Additionally, the increasing number of cases of infectious disease and rare disease like cancer cases and the rising geriatric population are expected to further enhance the market's growth rate in this region.
Asia-Pacific is estimated to be the fastest growing region in gene therapy market the forecast period 2023 - 2030
Asia-Pacific is expected to grow during the forecast period due to rapid development of medical facilities in emerging economies in this region. In addition to this, rising level of healthcare expenditure and increasing per-capita income are expected propel the market's growth rate in this region.
For more detailed information about the gene therapy market report, click here – https://www.databridgemarketresearch.com/es/reports/global-gene-therapy-market
